The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, to reduce LDL cholesterol in adults ...

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...

FDA has announced the approval of LIB Therapeutics’ Lerochol (lerodalcibep-liga) for subcutaneous (SC) use as an adjunct to ...

The US Food and Drug Administration has approved the use of lerodalcibep (Lerochol) to reduce LDL cholesterol alongside ...

LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced the U.S. Food and Drug ...

Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd , has entered into two strategic agreements with privately held Hasten ...

Scribe Therapeutics Inc. (Scribe), a genetic medicines company pioneering next-generation in vivo CRISPR-based medicines designed to be safe, durable, and effective enough to become standard-of-care ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

Being thin does not shield your heart from trouble. Slim people often carry high cholesterol that builds up in arteries year ...

A recent study from Mayo Clinic reveals that standard protocols for genetic screening overlook most people with familial ...